Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

486

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
AsthmaCOPD
Interventions
DRUG

levalbuterol HCl

Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.

DRUG

albuterol Sulfate

Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.

Trial Locations (18)

Unknown

Birmingham

Chula Vista

Oakland

Wheat Ridge

Waterbury

Washington D.C.

Brandon

Des Moines

Johnson City

Great Neck

Syracuse

Chapel Hill

Winston-Salem

Portland

Pittsburgh

Houston

San Antonio

Morgantown

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00667797 - Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects | Biotech Hunter | Biotech Hunter